{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:45:04Z","timestamp":1791510304482,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":873,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the efficacy and safety of chemoradiotherapy (RCT) combined with regional deep hyperthermia (RHT) of high-risk bladder cancer after transurethral resection of bladder tumor (TUR-BT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Between 1982 and 2016, 369 patients with pTa, pTis, pT1, and pT2 cN0\u20131 cM0 bladder cancer were treated with a multimodal treatment after TUR-BT. All patients received radiotherapy (RT) of the bladder and regional lymph nodes. RCT was administered to 215 patients, RCT + RHT was administered to 79 patients, and RT was used in 75 patients. Treatment response was evaluated 4\u20136 weeks after treatment with TUR-BT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Complete response (CR) overall was 83% (290\/351), and in treatment groups was RT 68% (45\/66), RCT 86% (178\/208), and RCT + RHT 87% (67\/77). CR was significantly improved by concurrent RCT compared with RT (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.05\u20135.12; p = .037), less influenced by hyperthermia (OR, 2.56; 95% CI, 0.88\u20138.00; p = .092). Overall survival (OS) after RCT was superior to RT (hazard ratio [HR], 0.7; 95% CI, 0.50\u20130.99; p = .045). Five-year OS from unadjusted Kaplan-Meier estimates was RCT 64% versus RT 45%. Additional RHT increased 5-year OS to 87% (HR, 0.32; 95% CI, 0.18\u20130.58; p = .0001). RCT + RHT compared with RCT showed a significantly better bladder-preservation rate (HR, 0.13; 95% CI, 0.03\u20130.56; p = .006). Median follow-up was 71 months. The median number of RHT sessions was five.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The multimodal treatment consisted of a maximal TUR-BT followed by RT; concomitant platinum-based chemotherapy combined with RHT in patients with high-grade bladder cancer improves local control, bladder-preservation rate, and OS. It offers a promising alternative to surgical therapies like radical cystectomy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Radical cystectomy with appropriate lymph node dissection has long represented the standard of care for muscle-invasive bladder cancer in medically fit patients, despite many centers reporting excellent long-term results for bladder preserving strategies. This retrospective analysis compares different therapeutic modalities in bladder-preservation therapy. The results of this study show that multimodal treatment consisting of maximal transurethral resection of bladder tumor followed by radiotherapy, concomitant platinum-based chemotherapy combined with regional deep hyperthermia in patients with Ta, Tis, T1\u20132 bladder carcinomas improves local control, bladder-preservation rate, and survival. More importantly, these findings offer a promising alternative to surgical therapies like radical cystectomy. The authors hope that, in the future, closer collaboration between urologists and radiotherapists will further improve treatments and therapies for the benefit of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0280","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T18:35:11Z","timestamp":1562783711000},"page":"e1341-e1350","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)"],"prefix":"10.1093","volume":"24","author":[{"given":"Ricarda","family":"Merten","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bertz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Keck","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"Department of Urology, Martha Maria Medical Center, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Michael","family":"R\u00f6del","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Universit\u00e4tsklinikum Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Klinikum Darmstadt GmbH, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gall","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Uter","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen Friedrich-Alexander-University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"2021122508161095900_onco12952-bib-0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"2021122508161095900_onco12952-bib-0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: A high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"key":"2021122508161095900_onco12952-bib-0003","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508161095900_onco12952-bib-0004","first-page":"985","article-title":"15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment","volume":"31","author":"Krause","year":"2011","journal-title":"Anticancer Res"},{"key":"2021122508161095900_onco12952-bib-0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"2021122508161095900_onco12952-bib-0006","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00066-017-1139-4","article-title":"T1\u20132 glottic cancer treated with radiotherapy and\/or surgery","volume":"193","author":"Shelan","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"2021122508161095900_onco12952-bib-0007","first-page":"1322","article-title":"Evaluating organ preservation outcome as treatment endpoint for T1aN0 glottic cancer","volume":"176","author":"Low","year":"2016","journal-title":"Laryngoscope"},{"key":"2021122508161095900_onco12952-bib-0008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.rpor.2014.02.001","article-title":"Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile","volume":"19","author":"Russo","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"2021122508161095900_onco12952-bib-0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/BF02238600","article-title":"Combined therapy for cancer of the anal canal: A preliminary report. 1974","volume":"36","author":"Nigro","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"2021122508161095900_onco12952-bib-0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0360-3016(90)90497-8","article-title":"Radiotherapy with and without cisplatin in bladder cancer","volume":"19","author":"Sauer","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122508161095900_onco12952-bib-0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1148\/radiology.173.2.2477869","article-title":"Superficial chest wall recurrences of breast cancer: Prognostic treatment factors for combined radiation therapy and hyperthermia","volume":"173","author":"Seegenschmiedt","year":"1989","journal-title":"Radiology"},{"key":"2021122508161095900_onco12952-bib-0012","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122508161095900_onco12952-bib-0013","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.radonc.2009.09.018","article-title":"Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia","volume":"93","author":"Wittlinger","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122508161095900_onco12952-bib-0014","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000447361","article-title":"How octogenarians with bladder cancer are treated in a maximum-care hospital: The real-life experience","volume":"98","author":"Sikic","year":"2017","journal-title":"Urol Int"},{"key":"2021122508161095900_onco12952-bib-0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2021122508161095900_onco12952-bib-0016","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0360-3016(95)00057-6","article-title":"Overview: Late effects of normal tissues (LENT) scoring system","volume":"31","author":"Rubin","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122508161095900_onco12952-bib-0017","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/jama.2010.1525","article-title":"AJCC cancer staging manual","volume":"304","author":"Egner","year":"2010","journal-title":"JAMA"},{"key":"2021122508161095900_onco12952-bib-0018","first-page":"137","article-title":"TNM classification of malignant tumors: A new 1987 edition","volume":"8","author":"Hermanek","year":"1987","journal-title":"Pathologe"},{"key":"2021122508161095900_onco12952-bib-0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/02656738709140402","article-title":"Thermal dose and time-temperature factors for biological responses to heat shock","volume":"3","author":"Gerner","year":"1987","journal-title":"Int J Hyperthermia"},{"key":"2021122508161095900_onco12952-bib-0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1040-8428(01)00179-2","article-title":"The cellular and molecular basis of hyperthermia","volume":"43","author":"Hildebrandt","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122508161095900_onco12952-bib-0021","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2013"},{"key":"2021122508161095900_onco12952-bib-0022","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1200\/JCO.2014.58.5521","article-title":"Organ-sparing multimodality treatment for muscle-invasive bladder cancer: Can we continue to ignore the evidence?","volume":"32","author":"R\u00f6del","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508161095900_onco12952-bib-0023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol Int"},{"key":"2021122508161095900_onco12952-bib-0024","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2013A homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122508161095900_onco12952-bib-0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2003.09.011","article-title":"Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: A survey including 1131 patients treated during 1990-2000 in Japan","volume":"45","author":"Nishiyama","year":"2004","journal-title":"Eur Urol"},{"key":"2021122508161095900_onco12952-bib-0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","article-title":"Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder","volume":"151","author":"Amling","year":"1994","journal-title":"J Urol"},{"key":"2021122508161095900_onco12952-bib-0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-5347(17)38244-7","article-title":"Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification","volume":"145","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"2021122508161095900_onco12952-bib-0028","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1464-410X.2010.09548.x","article-title":"Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: Analysis of patient outcomes in a contemporary series","volume":"107","author":"Gakis","year":"2011","journal-title":"BJU Int"},{"key":"2021122508161095900_onco12952-bib-0029","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"2021122508161095900_onco12952-bib-0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.urology.2016.05.041","article-title":"Bladder preservation therapy: A review of the literature and future directions","volume":"96","author":"Cahn","year":"2016","journal-title":"Urology"},{"key":"2021122508161095900_onco12952-bib-0031","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"2021122508161095900_onco12952-bib-0032","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2014.11.007","article-title":"A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)","volume":"94","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122508161095900_onco12952-bib-0033","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00066-017-1241-7","article-title":"Reirradiation + hyperthermia for recurrent breast cancer en cuirasse","volume":"194","author":"Oldenborg","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"2021122508161095900_onco12952-bib-0034","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","article-title":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study","volume":"11","author":"Issels","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122508161095900_onco12952-bib-0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/02656736.2016.1157903","article-title":"A systematic review of regional hyperthermia therapy in bladder cancer","volume":"32","author":"Longo","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"2021122508161095900_onco12952-bib-0036","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122508161095900_onco12952-bib-0037","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0360-3016(95)02152-3","article-title":"Feasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer","volume":"34","author":"Rietbroek","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"2021122508161095900_onco12952-bib-0038","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00686926","article-title":"Single instillation of hydroxypropylcellulose-doxorubicin as treatment for superficial bladder carcinoma","volume":"35","author":"Ueda","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122508161095900_onco12952-bib-0039","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(00)02059-6","article-title":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial","volume":"355","author":"Zee","year":"2000","journal-title":"Lancet"},{"key":"2021122508161095900_onco12952-bib-0040","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/02656736.2012.677933","article-title":"Old and new facts about hyperthermia-induced modulations of the immune system","volume":"28","author":"Frey","year":"2012","journal-title":"Int J Hyperthermia"},{"key":"2021122508161095900_onco12952-bib-0041","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/02656736.2015.1106011","article-title":"Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo","volume":"32","author":"Werthm\u00f6ller","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"2021122508161095900_onco12952-bib-0042","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00066-016-1057-x","article-title":"Simultaneous integrated protection: A new concept for high-precision radiation therapy","volume":"192","author":"Brunner","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"2021122508161095900_onco12952-bib-0043","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2007.06.030","article-title":"Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center","volume":"70","author":"Kotwal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0280","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/e1341\/41918369\/oncolo_24_12_e1341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/e1341\/41918369\/oncolo_24_12_e1341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:17:35Z","timestamp":1640420255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/12\/e1341\/6439501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,7,10]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0280","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,7,10]]}}}